Journal Of Bioactive And Compatible Polymers

Journal of Bioactive and Compatible Polymers is a bimonthly peer-reviewed journal from SAGE Publications in London, concerned with polymers whose behaviour in contact with living systems shapes therapeutic or diagnostic outcomes.《生物活性与相容聚合物杂志》由 SAGE Publications 在伦敦出版，为双月刊，关注与生命体系接触时行为足以影响疗效或诊断结果的聚合物材料。

Founded in 1986, the title works the ground between polymer chemistry, materials science and pharmaceutics, and its 2025 Journal Impact Factor of 1.9 places it among the smaller specialist journals in three Web of Science categories.该刊创办于 1986 年，活动范围落在高分子化学、材料科学与药剂学之间，2025 年影响因子为 1.9，在 Web of Science 的三个类别中属于规模较小的专业期刊。

Scope

• Biomedical polymers make up a narrow corner of materials research, and the journal singles out pharmacology as the field where their use and importance have grown fastest.生物医用聚合物在材料研究中只占一角，刊物把药剂学视为这类材料用途与分量增长最快的领域。
• Polymeric drugs and the design of polymer-based therapeutic agents form the historical core of the remit, running from synthesis and structure-activity reasoning through to performance in vivo.聚合物药物与聚合物治疗剂的设计构成选题的历史核心，从合成与构效推演一路延伸到体内表现。
• Functionalization of polymer chains, and the structures that follow from it, interest the editors mainly for their bearing on biological activity or on compatibility with tissue and blood.聚合物链的功能化以及由此形成的结构，主要按其对生物活性、或对组织与血液相容性的影响受到关注。
• Chemical modification of natural polymers receives steady attention, since polysaccharides and proteins remain the most accessible starting materials for implants, dressings and injectable depots.天然高分子的化学改性持续受到关注，多糖与蛋白质仍是植入体、敷料与可注射储库最易获得的起始原料。
• Scaffolds for tissue engineering and regeneration are read as porous architectures whose degradation rate, pore geometry and mechanical profile have to match the tissue being rebuilt.组织工程与再生用支架被当作多孔结构来读，其降解速率、孔隙形貌与力学特征须与所要重建的组织相称。
• Prodrug architectures built on polymer backbones let a latent active agent be released by a designed trigger, replacing the plain diffusion out of a matrix.以聚合物为主链的前药结构让潜在活性物按预设触发方式释放，取代活性物自基质中简单扩散的做法。
• Drug delivery and targeting are treated as one problem, in which circulation time, biodistribution and the chemistry of the targeting ligand are weighed together.药物递送与靶向被当作同一个问题处理，循环时间、体内分布与靶向配体的化学在此一并权衡。
• Polymer biosensors and stimuli-responsive systems form another strand, where a shift in conformation or solubility becomes a measurable signal or a controlled release event.聚合物生物传感器与刺激响应体系构成另一条线索，构象或溶解性的变化在此变成可测信号或受控释放事件。
• Assembled systems such as micelles, vesicles and layer-by-layer films are examined for the way supramolecular organisation governs loading capacity and the later fate of the carrier.胶束、囊泡与层层组装膜等组装体系，研究重点在于超分子组织方式如何支配载药量以及载体此后的去向。
• Biodegradable polymers meant for biological use are judged on two grounds at once, the identity of their degradation products and the time over which mechanical function disappears.面向生物用途的可降解聚合物同时受两条标准检验，即降解产物的身份与力学功能消失所经历的时间。
• Enzyme-sensitive polymer systems, with the modelling and modification that make them selective, carry the journal's long interest in biological recognition written into synthetic chains.酶敏感聚合物体系连同赋予其选择性的建模与改性，承载了刊物把生物识别写入合成链的长期兴趣。
• Biorelevant polymers with unusual properties, among them surfaces that resist protein adsorption or steer cell adhesion, complete the scope set out in the journal's own aims statement.具备特殊性能的生物相关聚合物，其中有能抵抗蛋白吸附或引导细胞黏附的表面，补全了刊物自述宗旨所划定的范围。
• A submission is expected to tie a materials result to a biological question, so a report of synthesis without functional evidence falls outside what the editors will send for review.来稿须把材料学结果与生物学问题系在一起，只报告合成而缺乏功能证据的稿件不会被送出评审。

History

• Volume 1 appeared in 1986 under Technomic Publishing Company of Lancaster, Pennsylvania, a technical house that had assembled a cluster of applied polymer and plastics journals.第 1 卷于 1986 年由宾夕法尼亚州兰开斯特的 Technomic Publishing Company 推出，这家技术出版机构此前已聚集了一批应用高分子与塑料类期刊。
• The title was positioned for a small specialist readership at a moment when degradable sutures and controlled-release implants were moving from laboratory work into clinical practice.刊物面向的是规模不大的专业读者，其时可降解缝线与控释植入体正从实验室工作转入临床实践。
• Issues were quarterly for the first thirteen volumes, a rhythm that held from 1986 through 1998 and suited a field where one complete study could take years.最初十三个卷为季刊，这一节奏从 1986 年延续到 1998 年，契合一个完整研究往往耗时数年的领域。
• From 1999 the schedule changed to six issues a year, and the National Library of Medicine records the bimonthly pattern as beginning in that year.1999 年起刊期改为每年 6 期，美国国家医学图书馆的著录也从这一年起记为双月刊。
• The name itself has never been altered, so the 1986 title, the abbreviation J Bioact Compat Polym and the stated scope remain recognisable to authors four decades on.刊名本身从未改动，1986 年的题名、缩写 J Bioact Compat Polym 与既定范围在四十年后对作者仍可辨认。
• Ownership passed to SAGE Publications, and the imprint recorded by the National Library of Medicine shifted from Lancaster, Pennsylvania to London, where the editorial office now sits.出版权此后转入 SAGE Publications，美国国家医学图书馆著录的出版地从宾夕法尼亚州兰开斯特改为伦敦，编辑部现设在那里。
• An electronic edition registered under ISSN 1530-8030 followed the print run, and with the back file digitised Crossref now holds 1,476 records, the 1986 opening volume among them.印刷版之后出现以 ISSN 1530-8030 登记的电子版，过刊一并数字化，Crossref 现收录 1476 条记录，1986 年的创刊卷也在其中。
• Indexing has held steady: Science Citation Index Expanded covers the title without a break, and three JCR categories carry its rankings, in biotechnology, biomaterials and polymer science.收录状况保持稳定，Science Citation Index Expanded 不曾中断覆盖该刊，三个 JCR 类别承载其分区排名，即生物技术、生物材料与高分子科学。
• MEDLINE and PubMed list the journal for selected citations only, an arrangement set by the indexing agreement rather than by any judgement on the quality of individual papers.MEDLINE 与 PubMed 均按选择性引用方式收录，这一安排由收录协议决定，与单篇论文的质量评价无关。
• Impact factors have stayed near 2 through the past decade, at 1.756 in 2021, 2.137 in 2022, 2.1 in 2023 and 2.2 in 2024, before easing to 1.9 for 2025.影响因子在近十年大体停在 2 附近，2021 年为 1.756，2022 年为 2.137，2023 年为 2.1，2024 年升至 2.2，2025 年略有回落。
• Output stays deliberately small at roughly nineteen articles a year, and a 2025 citation total of 1,012 against a cited half-life of 8.1 years suggests a slowly accumulating literature.年发文量有意保持精简，约 19 篇，2025 年被引总数 1012 次，被引半衰期 8.1 年，呈现的是一种缓慢积累的文献面貌。
• Two of the three categories now place the journal in the fourth quartile, with polymer science strongest at 72nd of 96 titles and biomaterials at 48th of 58.三个类别中有两个把该刊放在第四区，高分子科学表现最好，在 96 种期刊中列第 72 位，生物材料类别在 58 种中列第 48 位。
• Access remains subscription based with a hybrid route, and gold open access accounted for 3.19 percent of 2025 output, a share common among small specialist titles.访问方式仍以订阅为主并保留混合通道，金色开放获取占 2025 年发文量的 3.19%，这一比例在小型专业刊中颇为常见。
• Citation numbers of this size mean the journal is read within its own community rather than across disciplines, a pattern consistent with its narrow remit and low annual output.这样的被引体量说明读者集中在刊物自身的学术社群之内，跨学科传播有限，这与狭窄的收稿范围、偏低的年发文量彼此吻合。

Editors

• The journal describes itself as fully peer reviewed, and every research manuscript passes editorial screening before independent referees are approached.刊物自述为完全同行评审，每篇研究稿都先经编辑初筛，再送独立审稿人。
• Routine correspondence runs through the editorial office at the publisher's London address in Olivers Yard, just off City Road, where the SAGE journal team is based.日常联络由编辑部承担，办公地点在出版方位于伦敦 Olivers Yard 的地址，紧邻 City Road，SAGE 期刊团队也在此办公。
• The editorial board is listed on the journal's SAGE page with affiliations attached, and membership is renewed as terms expire.编委名单连同单位信息登在刊物的 SAGE 页面上，成员随任期届满更替。
• Editors and referees are drawn from polymer science and from the clinical materials field, so a manuscript meets readers who know both the synthesis and the use the material is meant for.编辑与审稿人来自高分子科学与临床材料两个圈子，一份稿子会交到既懂合成、也懂材料用途的人手上。
• Referees are picked for competence in the submitted topic, and their reports are used to test whether the biological evidence really supports the materials claim on offer.审稿人按稿件主题的具体专长遴选，其意见用于检验生物学证据是否真正支撑所提出的材料学论断。
• Referee identities stay hidden from authors, and the handling editor decides once the reports have been weighed against the stated scope of the journal.审稿人身份对作者保密，处理编辑在把各份意见与刊物既定范围放在一起权衡后作出决定。
• Manuscripts enter through the publisher's online submission system, which keeps the manuscript file, the reviewer correspondence and the decision letter in one record.稿件经出版方的在线投稿系统进入流程，稿件文件、审稿往来与决定函都留在同一份档案里。
• Scope fit is settled early, since a study of a polymer with no biological interface lies outside a remit defined by bioactivity and compatibility.选题是否合于范围在早期就有结论，不涉及生物界面的聚合物研究落在以生物活性与相容性界定的收稿范围之外。
• Associate editors handle manuscripts within their own specialism, which keeps technical judgement close to the subject and shortens the road to a first decision.副主编按各自专长分管稿件，技术判断因此贴近主题，通往首次决定的路程也随之缩短。
• Accepted papers pass to the publisher's production team for copy-editing, typesetting and DOI assignment before the article is posted online.录用稿交由出版方的生产团队做文字编辑、排版与 DOI 分配，随后在线上发布。
• Ethical oversight follows the publisher's publication ethics guidelines, which cover authorship, data integrity, competing interests and the handling of corrections.伦理监督依照出版方的出版伦理准则进行，涵盖作者身份、数据完整性、利益冲突与更正处理。
• Corresponding authors declare funding and competing interests at submission, and authorship disputes or correction notices are settled under the same publisher guidance.通讯作者在投稿时申明资助来源与利益冲突，作者身份争议与更正声明按同一套出版方准则处理。
• With no learned society behind it, editorial policy is set by the editors together with the publisher instead of by a membership assembly.刊物没有学会背景，编辑方针由编辑与出版方共同确定，不经会员大会表决。